Evidence map›Paper›PMID 36747136›Full record

ArticleBMC infectious diseases2023

The clinical outcomes of COVID-19 critically ill patients co-infected with other respiratory viruses: a multicenter, cohort study.

Khalid Al Sulaiman, Ohoud Aljuhani, Hisham A Badreldin, Ghazwa B Korayem, Abeer A Alenazi, Ahlam H Alharbi, Albandari Alghamdi, Alaa Alhubaishi, Ali F Altebainawi, Mohammad Bosaeed and 13 more

Erratum issuedOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 14 institutions in 2 countries.

Khalid Al SulaimanPharmaceutical Care Department, King Abdulaziz Medical City (KAMC)-Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia. alsulaimankh@hotmail.com.
Ohoud AljuhaniDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Hisham A BadreldinPharmaceutical Care Department, King Abdulaziz Medical City (KAMC)-Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia.
Ghazwa B KorayemDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia.
Abeer A AlenaziPharmaceutical Care Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Ahlam H AlharbiPharmaceutical Care Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Albandari AlghamdiDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia.
Alaa AlhubaishiDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia.
Ali F AltebainawiPharmaceutical Care Services, King Khalid Hospital, Hail Health Cluster, Hail, Saudi Arabia.
Mohammad BosaeedInfectious Disease Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Rand AlotaibiDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia.
Ahad AlawadDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia.
Nirvana AlnajjarDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia.
Khalid Bin SalehPharmaceutical Care Department, King Abdulaziz Medical City (KAMC)-Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia.
Walaa A SaitPharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
Samiah AlsohimiPharmaceutical Care Department, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Meshari M AlanizyCollege of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, PO Box 22490, Riyadh, 11426, Saudi Arabia.
Sarah A AlmuqbilCollege of Pharmacy, Qassim University, Qassim, Saudi Arabia.
Ibrahim Al SulaihimCentral Security Hospital, Riyadh, Saudi Arabia.
Ramesh VishwakarmaNorwich Medical School, University of East Anglia, Norwich, UK.
Mai AlalawiDepartment of Pharmaceutical Sciences, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia.
Fatimah AlhassanPharmaceutical Care Department, King Abdulaziz Medical City (KAMC)-Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia.
Suliman AlghnamPopulation Health Section, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Princess Nourah bint Abdulrahman University · SAKing Abdulaziz Medical City · SAKing Abdullah International Medical Research Center · SAKing Saud bin Abdulaziz University for Health Sciences · SARiyadh Armed Forces Hospital · SAKing Abdulaziz University · SAKing Fahd Armed Forces Hospital · SAKing Khaled Hospital · SANational Guard Health Affairs · SAQassim University · SASaudi Heart Association · SASecurity Forces Hospital · SASoliman Fakeeh Hospital · SAUniversity of East Anglia · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies have shown that non-critically ill COVID-19 patients co-infected with other respiratory viruses have poor clinical outcomes. However, limited studies focused on this co-infections in critically ill patients. This study aims to evaluate the clinical outcomes of critically ill patients infected with COVID-19 and co-infected by other respiratory viruses.

methodsA multicenter retrospective cohort study was conducted for all adult patients with COVID-19 who were hospitalized in the ICUs between March, 2020 and July, 2021. Eligible patients were sub-categorized into two groups based on simultaneous co-infection with other respiratory viruses throughout their ICU stay. Influenza A or B, Human Adenovirus (AdV), Human Coronavirus (i.e., 229E, HKU1, NL63, or OC43), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza virus, and Respiratory Syncytial Virus (RSV) were among the respiratory viral infections screened. Patients were followed until discharge from the hospital or in-hospital death.

resultsA total of 836 patients were included in the final analysis. Eleven patients (1.3%) were infected concomitantly with other respiratory viruses. Rhinovirus/Enterovirus (38.5%) was the most commonly reported co-infection. No difference was observed between the two groups regarding the 30-day mortality (HR 0.39, 95% CI 0.13, 1.20; p = 0.10). The in-hospital mortality was significantly lower among co-infected patients with other respiratory viruses compared with patients who were infected with COVID-19 alone (HR 0.32 95% CI 0.10, 0.97; p = 0.04). Patients concomitantly infected with other respiratory viruses had longer median mechanical ventilation (MV) duration and hospital length of stay (LOS).

conclusionCritically ill patients with COVID-19 who were concomitantly infected with other respiratory viruses had comparable 30-day mortality to those not concomitantly infected. Further proactive testing and care may be required in the case of co-infection with respiratory viruses and COVID-19. The results of our study need to be confirmed by larger studies.

Indexed as

CoinfectionCOVID-19Respiratory Syncytial Virus, HumanRespiratory Tract InfectionsVirusesAdultCohort StudiesHospital MortalityHumansRetrospective StudiesRhinovirusCoinfectionCoronavirus diseaseCOVID19Critically illMortalityMV durationOutcomesRespiratory viruses

Identifiers

PMID36747136
PMCPMC9901824
OpenAlexW4319333677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.